Adham S, Miranda S, Doucet J, Lévesque H, Benhamou Y
Centre de référence des maladies vasculaires rares, service de génétique, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France.
Département de médecine interne, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
Rev Med Interne. 2018 Jan;39(1):42-49. doi: 10.1016/j.revmed.2017.08.002. Epub 2017 Aug 31.
Cardiovascular events are the second leading cause of death in France. The assessment of overall cardiovascular risk using a personalized assessment with weighting risk factors can predict the risk of cardiovascular events in ten years. The validated treatments to reduce cardiovascular mortality in primary prevention are few. The use of statins in primary prevention is discussed. We report in this review the updated conclusions from clinical trials regarding the treatment with statins in primary prevention.
心血管事件是法国第二大致死原因。采用个性化评估并对风险因素进行加权来评估总体心血管风险，可预测十年内心血管事件的风险。在一级预防中，经证实可降低心血管死亡率的治疗方法很少。他汀类药物在一级预防中的使用存在争议。在本综述中，我们报告了关于他汀类药物在一级预防中治疗的临床试验的最新结论。
